Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management

RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted a lot of research on the application of RNA therapeutics technology in th...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang Dui, Zhao Xiaobin, Zhang Haifeng, Dang Lijuan, Huang Wenhui, Zhang Zhengfeng, Song Jinling
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546515/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849344313466552320
author Wang Dui
Zhao Xiaobin
Zhang Haifeng
Dang Lijuan
Huang Wenhui
Zhang Zhengfeng
Song Jinling
author_facet Wang Dui
Zhao Xiaobin
Zhang Haifeng
Dang Lijuan
Huang Wenhui
Zhang Zhengfeng
Song Jinling
author_sort Wang Dui
collection DOAJ
description RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted a lot of research on the application of RNA therapeutics technology in the treatment of CVDs. Despite hurdles in off-target effects and immune responses, the clinical trial outcomes are encouraging. This review synthesizes the current progress in RNA therapeutics for CVDs, examining their mechanisms, advantages, and challenges in delivery and safety. We highlight the potential of personalized medicine, combination artificial intelligence (AI) and bioinformatics in advancing RNA therapeutics. The future of RNA therapeutics in CVDs is poised for significant impact, necessitating continued research and interdisciplinary collaboration to optimize these treatments and ensure patient safety and efficacy.
format Article
id doaj-art-fe090b34a9834f51881e9299c1955b86
institution Kabale University
issn 2297-055X
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj-art-fe090b34a9834f51881e9299c1955b862025-08-20T03:42:41ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-03-011210.3389/fcvm.2025.15465151546515Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease managementWang Dui0Zhao Xiaobin1Zhang Haifeng2Dang Lijuan3Huang Wenhui4Zhang Zhengfeng5Song Jinling6Department of Cardiovascular Rehabilitation, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, ChinaDepartment of Cardiovascular Rehabilitation, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, ChinaDepartment of Cardiovascular Rehabilitation, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, ChinaDepartment of Endocrinology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, ChinaCardiovascular Department, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, ChinaDepartment of Cardiovascular Rehabilitation, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, ChinaDepartment of Cardiovascular Rehabilitation, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, ChinaRNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted a lot of research on the application of RNA therapeutics technology in the treatment of CVDs. Despite hurdles in off-target effects and immune responses, the clinical trial outcomes are encouraging. This review synthesizes the current progress in RNA therapeutics for CVDs, examining their mechanisms, advantages, and challenges in delivery and safety. We highlight the potential of personalized medicine, combination artificial intelligence (AI) and bioinformatics in advancing RNA therapeutics. The future of RNA therapeutics in CVDs is poised for significant impact, necessitating continued research and interdisciplinary collaboration to optimize these treatments and ensure patient safety and efficacy.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546515/fullcardiovascular diseasesRNA therapeuticsmRNAsiRNAmiRNARNA aptamers
spellingShingle Wang Dui
Zhao Xiaobin
Zhang Haifeng
Dang Lijuan
Huang Wenhui
Zhang Zhengfeng
Song Jinling
Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management
Frontiers in Cardiovascular Medicine
cardiovascular diseases
RNA therapeutics
mRNA
siRNA
miRNA
RNA aptamers
title Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management
title_full Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management
title_fullStr Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management
title_full_unstemmed Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management
title_short Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management
title_sort harnessing rna therapeutics novel approaches and emerging strategies for cardiovascular disease management
topic cardiovascular diseases
RNA therapeutics
mRNA
siRNA
miRNA
RNA aptamers
url https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546515/full
work_keys_str_mv AT wangdui harnessingrnatherapeuticsnovelapproachesandemergingstrategiesforcardiovasculardiseasemanagement
AT zhaoxiaobin harnessingrnatherapeuticsnovelapproachesandemergingstrategiesforcardiovasculardiseasemanagement
AT zhanghaifeng harnessingrnatherapeuticsnovelapproachesandemergingstrategiesforcardiovasculardiseasemanagement
AT danglijuan harnessingrnatherapeuticsnovelapproachesandemergingstrategiesforcardiovasculardiseasemanagement
AT huangwenhui harnessingrnatherapeuticsnovelapproachesandemergingstrategiesforcardiovasculardiseasemanagement
AT zhangzhengfeng harnessingrnatherapeuticsnovelapproachesandemergingstrategiesforcardiovasculardiseasemanagement
AT songjinling harnessingrnatherapeuticsnovelapproachesandemergingstrategiesforcardiovasculardiseasemanagement